Nuvation Bio
Nuvation Bio is a late-stage global oncology company founded in 2018, focused on developing novel therapeutic candidates for difficult-to-treat cancers.
Company History
Nuvation Bio was founded in 2018. Since its inception, the company has focused on developing oncology treatments for patients with difficult-to-treat cancers. Over the years, Nuvation Bio has expanded its operations with offices in New York, San Francisco, and Shanghai. Notable company milestones include closing a transaction with Panacea and debuting as a publicly traded company on the New York Stock Exchange under the ticker symbol 'NUVB.'
Services
Nuvation Bio is committed to the development of innovative cancer therapies. The company's services are primarily centered around conducting clinical trials for its investigational drugs. These trials are aimed at evaluating the efficacy and safety of novel therapeutic candidates. Nuvation Bio’s investigational drugs are accessible exclusively through these clinical trials, which are listed on ClinicalTrials.gov.
Therapeutic Pipeline
Nuvation Bio is developing a deep pipeline of differentiated and novel therapeutic candidates targeting critical cancer pathways. The pipeline includes Taletrectinib, a ROS1 inhibitor in Phase 2 trials for ROS1-positive non-small cell lung cancer; Safusidenib, a mIDH1 inhibitor in a Phase 2 trial for IDH1-mutant glioma; NUV-868, a BD2-selective BET inhibitor in Phase 1b studies; and NUV-1511, a drug-conjugate clinical candidate in Phase 1 trials for advanced solid tumors.
Clinical Trials
Nuvation Bio is conducting multiple clinical trials for its investigational drugs. Taletrectinib is in Phase 2 trials for ROS1-positive NSCLC. Safusidenib is in a global Phase 2 trial for IDH1-mutant glioma. NUV-868 is being studied in Phase 1b dose escalation studies in combination with olaparib and enzalutamide. NUV-1511 is in Phase 1 dose escalation studies for advanced solid tumors. These trials can be found on ClinicalTrials.gov.
Special Designations
Nuvation Bio has received several regulatory designations for its investigational drugs. Taletrectinib has been granted Breakthrough Therapy Designations by both the U.S. FDA and China’s NMPA for ROS1-positive NSCLC. NUV-422 has been granted Orphan Drug Designation for the treatment of malignant gliomas. Such designations underscore the potential significance of these therapies in addressing unmet medical needs.